We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
1 watching
Current Price
$1.52
$0.1
(7.04%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
49.53M
52-Week High
13.29
52-Week Low
1.34
Average Volume
0.07M
Dividend Yield
--
P/E Ratio
--
Market Capitalization49.53M
52-Week High13.29
52-Week Low1.34
Average Volume0.07M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company s antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
6 months ago
CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its first quarter ended March 31, 2022. The Company ...
Ticker Report
6 months ago
Pyxis Oncology, Inc. (NASDAQ:PYXS Get Rating) was the target of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 421,500 shares, a decline of 21.7% from the March 31st total of 538,500 shares. Approximately 2.1% of the shares ...
Globe Newswire
7 months ago
- Data highlight PYX-106s differentiated activity profile and antitumor activity in an in vivo mouse model - - Preclinical data support IND filing in 2H 2022 - CAMBRIDGE, Mass. and NEWARK, Del. and NANJING, China, April 08, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced...
PR Newswire
8 months ago
Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology PR Newswire NEWARK, Del. and NANJING, China, March 29, 2022 - Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$1.52
$0.1
(7.04%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00